Beranda › Osteosarkoma › North Carolina
Uji klinis Osteosarkoma di North Carolina
6 studi untuk Osteosarkoma mencari peserta di lokasi di North Carolina.
Kota di North Carolina
Teks studi resmi (Bahasa Inggris)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Duke University Medical Center, Durham
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT04616560The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Children's Hospital, Charlotte
- Novant Health Hemby Children's Hospital, Charlotte
- dan 3 lainnya
Menerima pesertaFase 2
Usia 7 hingga 22 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07560826Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- dan 2 lainnya
Menerima pesertaFase 3
Hingga usia 50 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05235165SPEARHEAD-3 Pediatric Study
- Duke University School of Medicine, Durham
Menerima pesertaFase 1/2
Usia 2 hingga 21 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05642455Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Mission Hospital, Asheville
- Wake Forest University Health Sciences, Winston-Salem
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT01790152Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Menerima pesertaFase 1
18 Months · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT03721068Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.